Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

Atlanticus Holdings Corp

Start price
Target price
Perf. (%)
€32.40
04.09.22
€11.00
04.09.23
-
17.09.22

Revenue growth >5% per year expected
Probably not worthwhile Investment
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
ShiftPixy Inc.

Start price
Target price
Perf. (%)
€31.30
10.09.22
€11.00
10.09.23
-37.16%
17.09.22

Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
buy
Bed Bath & Beyond Inc.

Start price
Target price
Perf. (%)
€7.24
06.09.22
-
06.09.23
10.02%
17.09.22

Capable Management
Good culture
Could be worthwhile Investment >10% per year
Little innovation
buy
Emcore Corp.

Start price
Target price
Perf. (%)
€3.06
21.10.20
€11.00
24.10.24
-32.94%
15.09.22

buy
Stratasys Inc.

Start price
Target price
Perf. (%)
€20.24
29.07.22
-
25.08.25
-19.39%
14.09.22

buy
Amyris Biotechnology Inc.

Start price
Target price
Perf. (%)
€5.00
23.12.21
-
23.12.22
-22.05%
13.09.22

Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth >5% per year expected
Rising EBIT margin expected
buy
Assembly Biosciences Inc.

Start price
Target price
Perf. (%)
€2.76
12.09.21
€3.00
12.09.22
-24.82%
13.09.22

Could be worthwhile Investment >10% per year
buy
Seres Therapeutics Inc

Start price
Target price
Perf. (%)
€4.99
12.09.21
€8.00
12.09.22
36.81%
13.09.22

Could be worthwhile Investment >10% per year
buy
Pro-Dex Inc.

Start price
Target price
Perf. (%)
€20.00
12.09.21
€23.00
12.09.22
-1.50%
13.09.22

Could be worthwhile Investment >10% per year
buy
Bed Bath & Beyond Inc.

Start price
Target price
Perf. (%)
€7.98
08.09.22
€9.00
08.09.23
11.61%
09.09.22

Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
High valuation
Novavax Inc.

Start price
Target price
Perf. (%)
€39.31
09.08.22
€30.00
09.08.23
-20.37%
09.09.22

Bed Bath & Beyond Inc.

Start price
Target price
Perf. (%)
€26.71
17.08.22
€5.00
17.08.23
-69.11%
09.09.22

Risky Investment
High risks for its business
buy
ShiftPixy Inc.

Start price
Target price
Perf. (%)
€13.48
05.09.22
-
05.09.23
113.53%
09.09.22

Revenue growth >5% per year expected
EBIT growth >5% per year expected
Probably not worthwhile Investment
Lower EBIT Margin than peer group
buy
RCI Hospitality Holdings Inc

Start price
Target price
Perf. (%)
€55.00
07.09.21
-
07.09.22
20.91%
08.09.22

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Good rating
EBIT growth >5% per year expected
buy
Codexis Inc.

Start price
Target price
Perf. (%)
€34.80
05.11.21
€50.00
31.12.23
-79.99%
07.09.22

Could be very worthwhile Investment >20% year
buy
Novavax Inc.

Start price
Target price
Perf. (%)
€202.35
31.08.21
€350.00
31.12.23
-85.81%
07.09.22

Could be worthwhile Investment >10% per year
buy
Novavax Inc.

Start price
Target price
Perf. (%)
€212.55
05.09.21
€333.00
05.09.22
-85.70%
06.09.22

Top 10 in its market
Could be worthwhile Investment >10% per year
Leading role in innovation
Very Future proof/growth oriented business model
buy
Bed Bath & Beyond Inc.

Start price
Target price
Perf. (%)
€9.88
22.08.22
€14.00
22.08.23
-17.77%
03.09.22

Capable Management
Good culture
Could be worthwhile Investment >10% per year
Little innovation
buy
Ziopharm Oncology

Start price
Target price
Perf. (%)
€1.99
07.09.21
€4.00
31.12.23
52.84%
01.09.22

Could be worthwhile Investment >10% per year
Plug Power Inc.

Start price
Target price
Perf. (%)
€28.35
27.08.22
€28.00
27.08.23
2.82%
30.08.22

Good rating
Revenue growth >5% per year expected
Higher EBIT margin than peer group
Fair valuation
buy
Novavax Inc.

Start price
Target price
Perf. (%)
€51.80
27.05.22
€68.00
27.05.23
-32.47%
27.08.22

Very low/no dividend yield expected
very negative Cash Flow expected
ROE lower than 10% per year
high free float
Bed Bath & Beyond Inc.

Start price
Target price
Perf. (%)
€9.57
09.08.22
€7.00
09.08.23
11.81%
27.08.22

Revenue growth >5% per year expected
Higher EBIT margin than peer group
Very low/no dividend yield expected
very negative Cash Flow expected
Tempest Therapeutics Inc.

Start price
Target price
Perf. (%)
€12.22
23.08.21
-
23.08.22
-78.40%
24.08.22

Risky Investment
Bed Bath & Beyond Inc.

Start price
Target price
Perf. (%)
€10.10
22.08.22
€10.00
22.08.23
-13.85%
23.08.22

Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
High valuation
Agile Therapeutics Inc.

Start price
Target price
Perf. (%)
€31.25
05.07.22
€5.00
05.07.23
-25.76%
23.08.22